




Searching News Database: clopidogrel
HSMN NewsFeed - 30 Oct 2024
Laura J. Seplavy, MS, Joins Perosphere as Executive Vice President, Marketing and External Relations
Laura J. Seplavy, MS, Joins Perosphere as Executive Vice President, Marketing and External Relations
HSMN NewsFeed - 9 Jul 2015
The Medicines Company Authorizes Generic Launch of ANGIOMAX(R) (bivalirudin)
The Medicines Company Authorizes Generic Launch of ANGIOMAX(R) (bivalirudin)
HSMN NewsFeed - 23 Dec 2013
European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Cangrelor
European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Cangrelor
HSMN NewsFeed - 30 Aug 2013
ITC Acquires Accumetrics to Form Leading POC Cardiovascular Diagnostics Business
ITC Acquires Accumetrics to Form Leading POC Cardiovascular Diagnostics Business
HSMN NewsFeed - 24 Jul 2012
Transgenomic Announces Medicare Coverage for Clopidogrel (Plavix(R)) Response Test
Transgenomic Announces Medicare Coverage for Clopidogrel (Plavix(R)) Response Test
HSMN NewsFeed - 9 Mar 2011
2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery
2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery
HSMN NewsFeed - 26 Jan 2011
Bristol-Myers Squibb and sanofi-aventis Announce U.S. FDA Decision to Grant Pediatric Exclusivity For PLAVIX
Bristol-Myers Squibb and sanofi-aventis Announce U.S. FDA Decision to Grant Pediatric Exclusivity For PLAVIX
HSMN NewsFeed - 29 Jul 2010
FDA Advisory Committee Recommends US FDA Approval of Brilinta (Ticagrelor) for Acute Coronary Syndromes
FDA Advisory Committee Recommends US FDA Approval of Brilinta (Ticagrelor) for Acute Coronary Syndromes
HSMN NewsFeed - 21 May 2009
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
HSMN NewsFeed - 13 May 2009
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
HSMN NewsFeed - 4 May 2009
AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
HSMN NewsFeed - 23 Feb 2009
European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
HSMN NewsFeed - 3 Feb 2009
Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee
Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee
HSMN NewsFeed - 26 Jan 2009
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
HSMN NewsFeed - 2 Sep 2008
New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients
New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients
HSMN NewsFeed - 9 Jul 2008
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
HSMN NewsFeed - 13 Dec 2007
PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
HSMN NewsFeed - 4 Dec 2007
Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
HSMN NewsFeed - 27 Sep 2007
FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
HSMN NewsFeed - 2 Jul 2007
NicOx appoints Pascal Pfister MD as Chief Scientific Officer and strengthens R&D organization
NicOx appoints Pascal Pfister MD as Chief Scientific Officer and strengthens R&D organization
HSMN NewsFeed - 19 Jun 2007
Sanofi-Aventis and Bristol-Myers Squibb Prevail in U.S. Plavix Patent Litigation
Sanofi-Aventis and Bristol-Myers Squibb Prevail in U.S. Plavix Patent Litigation
HSMN NewsFeed - 23 May 2007
Efficacy of OrbusNeich's Genous(TM) Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
Efficacy of OrbusNeich's Genous(TM) Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
HSMN NewsFeed - 22 May 2007
XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
HSMN NewsFeed - 22 May 2007
ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
HSMN NewsFeed - 24 Mar 2007
Schering-Plough's Novel Oral Thrombin Receptor Antagonist Meets Primary Endpoint in Phase II Trial
Schering-Plough's Novel Oral Thrombin Receptor Antagonist Meets Primary Endpoint in Phase II Trial
HSMN NewsFeed - 5 Dec 2006
American Heart Association Statement on Use of Drug-Eluting Coronary Stents
American Heart Association Statement on Use of Drug-Eluting Coronary Stents
HSMN NewsFeed - 11 May 2006
Conor Medsystems Initiates RAPID Clinical Study for First Pimecrolimus Drug-Eluting Stent
Conor Medsystems Initiates RAPID Clinical Study for First Pimecrolimus Drug-Eluting Stent
Additional items found! 45

Members Archive contains
45 additional stories matching:
clopidogrel
(Password required)
clopidogrel
(Password required)